Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 1,840
Revenue ttm —
Net income ttm (62)
Free cash flow ttm (48)
Net debt Q (349)
Valuation
P/E n/m
Forward P/E e —
Price / sales n/m
Forward P/S e Powerpack
Price / FCF n/m
Price / book 2.0
Financial health
Current ratio Q 21.6 (at or above 1.5: strong)
Debt / equity Q 0.0 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth e —
EPS growth e —
EPS growth e —
EPS growth, 5 yrs e —
Insiders
Net bought 12m 159
Sells 12m 0
Buys 12m 10
Owned by insiders 59.6%
Compound annual growth
10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — — — —
Gross margin, % — — — — — — — — — — — —
EBT — — — — — — — — — (66) (62) —
EBT margin, % — — — — — — — — — 0.00 0.00 —
Net income — — — — — — — — — (66) (62) —
Per share, $
Per share, $ Revenue — — — — — — — — — 0.00 0.00 —
Earnings — — — — — — — — — (17.20) (12.11) —
Cash flow — — — — — — — — — (0.52) (0.92) —
Capex — — — — — — — — — 0.00 0.00 —
Free cash flow — — — — — — — — — (0.52) (0.92) —
Book value — — — — — — — — — (17.15) 9.55 —
Shares, m — — — — — — — — — 4 18 —
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — — (2) (48) —
Capex — — — — — — — — — — — —
Free cash flow — — — — — — — — — (2) (48) —
Balance, $m
Balance, $m Working capital — — — — — — — — — 84 343 —
Net debt — — — — — — — — — (89) (349) —
Shareholders’ equity — — — — — — — — — (66) 498 —
Returns, %
Returns, % ROA — — — — — — — — — 0.00 0.00 —
ROIC — — — — — — — — — 0.00 (28.66) —
ROE — — — — — — — — — 0.00 0.00 —
People
People Employees — — — — — — — — — 30 — —
Revenue/emp, $m — — — — — — — — — 0.00 — —
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated 12 Nov 2026

Braveheart Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FTRE Fortrea Holdings Inc. $1.9B — (loss-making) — (loss-making) −1.40% (below 0%: shrinking) n/m −33.96% (below 0%: shrinking) 20.17% 2.17% Compare
TRVI Trevi Therapeutics, Inc. $1.9B — (loss-making) — — n/m −80.98% (below 0%: shrinking) 0.00% 0.00% Compare
AGIO Agios Pharmaceuticals, Inc. $1.9B — (loss-making) — (loss-making) +330.01% (above 0%: growing) n/m +32.64% (above 0%: growing) 95.44% (139.32%) Compare
LYCA Lycia Therapeutics Inc. $1.9B — — — — — — — Compare
ZBIO Zenas BioPharma, Inc. $1.9B — (loss-making) — (loss-making) — n/m −41.00% (below 0%: shrinking) 100.00% (1,034.09%) Compare
BRVE Braveheart Bio, Inc. $1.8B — (loss-making) — — n/m −3,193.65% (below 0%: shrinking) — 0.00%
COAG Hemab Therapeutics Holdings, Inc. $1.8B — (loss-making) — — n/m −84.73% (below 0%: shrinking) — 0.00% Compare
ZYME Zymeworks Inc. $1.8B 39.5× 21.1× FY26e +828.73% (above 0%: growing) n/m +24.23% (above 0%: growing) 85.91% 69.25% Compare
QURE uniQure N.V. $1.7B — (loss-making) — (loss-making) +40.39% (above 0%: growing) n/m −192.89% (below 0%: shrinking) 95.46% (1,019.63%) Compare
Median of peers $1.9B — — +185.20% — −41.00% 90.68% 0.00%

All 621 Biotechnology stocks →

stockrow.com/BRVE · Data as of Nov 12, 2026 · For information only; not investment advice. · © 2026 stockrow.com